



Stabilis



Ceftazidime



Nombre comercial

Bactazid	Chile
Bagram	México
Biotum	Polonia
Cefatril	Brasil
Cefidime	Egipto
Cefortam	Portugal
Ceftamil	Rumania
Ceftim	Italia
Ceftimira	Chile
Ceftram	Ecuador
Efadima	Chile
Fortam	España, Suiza
Fortaz	Brasil, Canadá, Estados Unidos de América
Fortum	Alemania, Argentina, Australia, Austria, Chile, Colombia, Dinamarca, Egipto, Emiratos Árabes Unidos, Francia, Gran Bretaña, Irlanda, Islandia, Marruecos, Marruecos, Noruega, Nueva Zelanda, Países Bajos, Polonia, Rumania, Suecia, Túnez, Turquía,
Ftazidime	Venezuela
Glazidim	Bélgica, Finlandia, Italia, Luxemburgo
Iesetum	Turquía
Intracef	Brasil
Kefadim	Arabia Saudita, Bélgica, Brasil, Egipto, Gran Bretaña, Marruecos
Kefamin	España
Kefazim	Austria
Kefzim	Sudafrica
Lorazidime	Irán
Negacef	Arabia Saudita, Emiratos Árabes Unidos
Novocral	Grecia
Panzid	Italia
Parzidime	Arabia Saudita
Pluseptic	Argentina
Sigmazidim	Egipto
Solvetan	Dinamarca, Grecia
Spectrum	Italia
Starcef	Italia
Sturdizime	México

Sumizidima	Colombia
Tazicef	Estados Unidos de América
Zadolina	México
Zidacef	Arabia Saudita
Zidime	Arabia Saudita, Emiratos Árabes Unidos, Marruecos
Zidimox	Portugal



Estabilidad en solución

		100 & 200 mg/ml	-20°C		91			445
		100 & 200 mg/ml	21°C-23°C		8			445
		100 & 200 mg/ml	4°C		96			445
		20 mg/ml	2-8°C		2			4922
		270 mg/ml	20°C		18			1857
		270 mg/ml	4°C		7			1857
		20 mg/ml	2-8°C		10			1452
		20 mg/ml	25°C		48			432
		20 mg/ml	25°C		2			1452
		40 mg/ml	20°C		20			1651
		40 mg/ml	35°C		20			1651
		20 mg/ml	25°C		48			432
		40 mg/ml	20°C		20			1651
		40 mg/ml	35°C		20			1651
		20 mg/ml	2-8°C		2			4922
PVC		30 & 60 mg/ml	-20°C		30			443
PVC		30 & 60 mg/ml	3°C		10			443
PVC		36,6 mg/ml	-20°C		30			440
PVC		60 mg/ml	-20°C		14			273

PVC		4 mg/ml	25°C		24			1656
PVC		4 mg/ml	4°C		7			1656
PVC		40 mg/ml	-10°C		90			585
PVC		40 mg/ml	20°C		20			1651
PVC		40 mg/ml	4°C		7			697
PVC		4 mg/ml	25°C		24			1656
PVC		4 mg/ml	4°C		7			1656
PVC		40 mg/ml	-10°C		90			585
PVC		40 mg/ml	4°C		7			697
PVC		0,1 mg/ml	25°C		24			2450
PVC		0,1 mg/ml	37°C		2			2450
PVC		0,1 mg/ml	4°C		4			2450
PVC		0,5 mg/ml	25°C		2			3888
PVC		0,5 mg/ml	37°C		6			3888
PVC		0,5 mg/ml	4°C		14			3888
PE		10 mg/ml	22°C		24			1067
PE		10 mg/ml	4°C		24			1067
PE		10 mg/ml	22°C		24			1067
PE		10 mg/ml	4°C		24			1067
PP		40 mg/ml	20°C		20			1651
PP		40 mg/ml	20°C		20			1651
POF		20 mg/ml	2-8°C		10			1452
POF		20 mg/ml	25°C		2			1452
EVA		20 mg/ml	23°C		24			1840
EVA		20 mg/ml	4°C		7			1840
PP		100 mg/ml	-20°C		91			477
PP		100 mg/ml	22°C		24			477
PP		100 mg/ml	4°C		10			477
PP		100 & 200 mg/ml	-20°C		91			445
PP		100 & 200 mg/ml	21°C-23°C		8			445
PP		100 & 200 mg/ml	4°C		96			445
PP		20 mg/ml	2-8°C		7			4922
PP		125 mg/ml	20-25°C		24			4634

		20 mg/ml	-20°C		90			4032
		20 mg/ml	2-8°C		7			4032
		125 mg/ml	20-25°C		8			4634
		20 mg/ml	2-8°C		2			4922
		120 mg/ml	27°C		16			287
		25 mg/ml	37°C		8			4634
		5 & 40 mg/ml	25°C		24			604
		5 & 40 mg/ml	4°C		7			604
		60 mg/ml	-20°C		14			817
		60 mg/ml	27°C		24			287
		60 mg/ml	4°C		14			817
		60 & 120 mg/ml	4°C		6			287
		25 mg/ml	37°C		8			4634
		5 & 40 mg/ml	25°C		24			604
		5 & 40 mg/ml	4°C		7			604
		12,5 mg/ml	32°C		12			4943
		25 mg/ml	32°C		8			4943
		12,5 mg/ml	32°C		12			4943
		120 mg/ml	25°C		24			2042
		120 mg/ml	37°C		8			2042



Estabilidad en mezcla

		10 mg/ml	23°C		Ranitidine hydrochloride : 0,5 mg/ml	4		360
		8,35 mg/ml	20°C-23°C		Granisetron hydrochloride : 0,5 mg/ml	4		57
		10 mg/ml	22°C-23°C		Ranitidine hydrochloride : 0,5 mg/ml	4		360
		20 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48		432
		40 mg/ml	25°C		Aminophylline : 2 mg/ml	2		900
		20 & 100 mg/ml	23°C-25°C		Tacrolimus : 5 & 20 µg/ml	4		814
		5 mg/ml	25°C		Tenoxicam : 0,2 mg/ml	96		1943
		20 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	24		432
		40 mg/ml	25°C		Aminophylline : 2 mg/ml	2		900

		5 mg/ml	25°C	?	Filgrastim : 40 µg/ml	4		104
		10 mg/ml	25°C	?	Ofloxacin : 2 mg/ml	48		889
PVC		5 mg/ml	25°C		Tenoxicam : 0,2 mg/ml	72		1943
PVC		5 mg/ml	4°C		Tenoxicam : 0,2 mg/ml	96		1943
PVC		10 mg/ml	8°C	?	Metronidazole : 5 mg/ml	72		282
PVC		0,5 mg/ml	24°C		Vancomycin hydrochloride : 1 mg/ml	24		1416
PVC		0,5 mg/ml	37°C		Vancomycin hydrochloride : 1 mg/ml	12		1416
PVC		0.125 mg/ml	37°C	?	Heparin sodium : 0.5 UI/ml	12		4056
PVC		0,5 mg/ml	4°C		Vancomycin hydrochloride : 1 mg/ml	24		1416
PVC		0.125 mg/ml	4°C	?	Heparin sodium : 0.5 UI/ml	120		4056
PVC		0,5 mg/ml	24°C		Vancomycin hydrochloride : 1 mg/ml	24		1416
PVC		0,5 mg/ml	37°C		Vancomycin hydrochloride : 1 mg/ml	12		1416
PVC		0,5 mg/ml	4°C		Vancomycin hydrochloride : 1 mg/ml	24		1416
PVC		0,125 mg/ml	24°C	?	Tobramycin sulfate : 0,008 mg/ml	16		2369
PVC		0,125 mg/ml	37°C	?	Tobramycin sulfate : 0,008 mg/ml	8		2369
PVC		0.125 mg/ml	37°C	?	Heparin sodium : 0.5 UI/ml	12		4056
PVC		0.125 mg/ml	4°C	?	Heparin sodium : 0.5 UI/ml	120		4056
PVC		0,5 mg/ml	25°C		Cefazolin sodium : 0,5 mg/ml	2		3888
PVC		0,125 mg/ml	25°C	?	Cefazolin sodium : 0,125 mg/ml	24		3651
PVC		0,5 mg/ml	37°C		Cefazolin sodium : 0,5 mg/ml	24		3888
PVC		0.125 mg/ml	37°C	?	Heparin sodium : 0.5 UI/ml	12		4056
PVC		0,125 mg/ml	37°C	?	Cefazolin sodium : 0,125 mg/ml	24		3651
PVC		0,125 mg/ml	4°C		Cefazolin sodium : 0,125 mg/ml	7		3651
PVC		0,5 mg/ml	4°C		Cefazolin sodium : 0,5 mg/ml	14		3888
PVC		0.125 mg/ml	4°C	?	Heparin sodium : 0.5 UI/ml	120		4056
POF		20 mg/ml	23°C		Linezolid : 2 mg/ml	24		1659
POF		20 mg/ml	4°C		Linezolid : 2 mg/ml	7		1659
?		16,7 mg/ml	22°C-28°C	?	Daptomycin : 16,7 mg/ml	2		1937



Factores que influyen sobre la estabilidad

				585
	NaH CO ₃			3543
				1651 1857 2141
				2450
	37°C			3651 3757
	pH > 10			1759
	pH > 9			3883
	pH < 4			1759



Compatibilidades

	Ceftazidime : 0,15 mg/ml		4693
	Ceftazidime : 40 mg/ml		1415
	Ceftazidime		3543
	Ceftazidime		3543
	Ceftazidime Aciclovir sodium		3883
	Ceftazidime : 100 mg/ml	RL	4603
	Ceftazidime	RL	3543
	Ceftazidime : 40 mg/ml		4370
	Ceftazidime		3883
	Ceftazidime : 10 mg/ml		4440
	Ceftazidime : 40 mg/ml		3967
	Ceftazidime : 20 mg/ml Aciclovir sodium : 5 mg/ml		336
	Ceftazidime : 40 mg/ml Allopurinol sodium : 3 mg/ml		307
	Ceftazidime : 40 mg/ml Amifostine : 10 mg/ml		3
	Ceftazidime Amikacin sulfate		3543
	Ceftazidime Amikacin sulfate		3883

		Ceftazidime : 125 mg/ml Amikacin sulfate : 15 mg/ml		2141
		Ceftazidime : 83.3 mg/ml Amikacin sulfate : 15 mg/ml		1759
		Ceftazidime Amikacin sulfate		3549
		Ceftazidime : 2 & 6 mg/ml Aminophylline : 1 & 2 mg/ml		900
		Ceftazidime : 0.32 mg/ml Aminophylline : 0.16 mg/ml		3696
		Ceftazidime : 2 & 6 mg/ml Aminophylline : 1 & 2 mg/ml		900
		Ceftazidime Aminophylline		3543
		Ceftazidime : 40 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Ceftazidime : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Ceftazidime Amphotericin B		3883
		Ceftazidime : 40 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Ceftazidime : 40 mg/ml Amsacrine : 1 mg/ml		253
		Ceftazidime : 40 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Ceftazidime : 80 mg/ml Azithromycine : 2 mg/ml		1800
		Ceftazidime : 40 mg/ml Aztreonam : 40 mg/ml		99
		Ceftazidime : 40 mg/ml Bivalirudin : 5 mg/ml		1713
		Ceftazidime : 34.5 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Ceftazidime : 100 mg/ml Caffeine : 10 mg/ml		3964
		Ceftazidime Calcium chloride		3883
		Ceftazidime Calcium gluconate		3883
		Ceftazidime : 40 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Ceftazidime : 40 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Ceftazidime : 40 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Ceftazidime : 20 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Ceftazidime : 20 mg/ml Ciprofloxacin lactate : 1 mg/ml		500
		Ceftazidime : 20 mg/ml Ciprofloxacin lactate : 1 mg/ml		500

		Ceftazidime		3883
		Ciprofloxacin lactate		
		Ceftazidime : 40 mg/ml Cisatracurium besylate : 0.1 & 2 mg/ml		299
		Ceftazidime : 20 mg/ml Clindamycin phosphate : 9 mg/ml		432
		Ceftazidime Clindamycin phosphate		3526
		Ceftazidime : 20 mg/ml Clindamycin phosphate : 9 mg/ml		432
		Ceftazidime Clindamycin phosphate		3526
		Ceftazidime		3883
		Ceftazidime : 40 mg/ml Cisatracurium besylate : 5 mg/ml		299
		Ceftazidime : 95 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Ceftazidime : 40 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Ceftazidime : 125 mg/ml Dopamine hydrochloride : 0.4 mg/ml		2141
		Ceftazidime : 40 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Ceftazidime : 60 mg/ml		316
		Ceftazidime : 200 mg/ml		939
		Ceftazidime : 5 mg/ml Colistin mesilate sodium : 1.5 mg/ml		3997
		Ceftazidime : 125 mg/ml Dobutamine hydrochloride : 1 mg/ml		2141
		Ceftazidime : 40 mg/ml		301
		Ceftazidime : 16,7 mg/ml Daptomycin : 16,7 mg/ml		1937
		Ceftazidime		3543
		Ceftazidime		3883
		Ceftazidime : 80 mg/ml Defibrotide : 8 mg/ml		3728
		Ceftazidime : 10 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Ceftazidime : 170 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Ceftazidime		3883
		Ceftazidime Daptomycin		2271
		Ceftazidime Dimenhydrinate		2087
		Ceftazidime		3543
		Ceftazidime : 40 mg/ml Docetaxel : 0.9 mg/ml		1754

	Ceftazidime : 40 mg/ml Doxapram hydrochloride : 2 mg/ml		1802
	Ceftazidime : 10 mg/ml Enalaprilate : 0.05 mg/ml		1315
	Ceftazidime : 125 mg/ml Epinephrine hydrochloride : 50 µg/ml		2141
	Ceftazidime : 40 mg/ml Eravacycline : 0,6 mg/ml		4434
	Ceftazidime Erythromycin lactobionate		3674
	Ceftazidime : 83.3 mg/ml Erythromycin lactobionate : 10 & 50 mg/ml		1759
	Ceftazidime : 125 mg/ml Erythromycin lactobionate : 5 mg/ml		2141
	Ceftazidime : 10 mg/ml Esmolol hydrochloride : 10 mg/ml		384
	Ceftazidime : 40 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Ceftazidime : 20 mg/ml Famotidine		397
	Ceftazidime : 20 mg/ml Famotidine : 2 mg/ml		215
	Ceftazidime : 40 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
	Ceftazidime : 40 mg/ml Filgrastim : 30 µg/ml		244
	Ceftazidime : 10 mg/ml Filgrastim : 40 µg/ml		104
	Ceftazidime : 40 >> 180 mg/ml Flucloxacillin sodium : 40 >> 240 mg/ml		3091
	Ceftazidime : 83.3 mg/ml Fluconazole : 2 mg/ml		1759
	Ceftazidime : 20 mg/ml Fluconazole : 2 mg/ml		496
	Ceftazidime Fluconazole		3883
	Ceftazidime : 40 mg/ml Fluconazole : 2 mg/ml		256
	Ceftazidime : 125 mg/ml Fluconazole : 2 mg/ml		2141
	Ceftazidime : 40 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Ceftazidime Foscarnet sodium		3883
	Ceftazidime : 20 mg/ml Foscarnet sodium : 24 mg/ml		73
	Ceftazidime : 20 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Ceftazidime : 20 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Ceftazidime : 40 mg/ml Fosfomycin : 30 mg/ml		4055

		Ceftazidime : 40 mg/ml Fosfomycin : 30 mg/ml		4055
		Ceftazidime : 125 mg/ml Furosemide : 10 mg/ml		2141
		Ceftazidime : 83.3 mg/ml Furosemide : 10 mg/ml		1759
		Ceftazidime : 100 mg/ml Gallium nitrate : 1 mg/ml		91
		Ceftazidime Ganciclovir sodium		3883
		Ceftazidime : 40 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Ceftazidime : 125 mg/ml Gentamicin sulfate : 6 mg/ml		2141
		Ceftazidime Gentamicin sulfate		3543
		Ceftazidime Gentamicin sulfate		3520
		Ceftazidime : 83.3 mg/ml Gentamicin sulfate : 6 mg/ml		1759
		Ceftazidime Gentamicin sulfate		3883
		Ceftazidime Gentamicin sulfate		3643
		Ceftazidime : 16.7 mg/ml Granisetron hydrochloride : 1 mg/ml		57
		Ceftazidime : 0.125 mg/ml Heparin sodium : 0.5 UI/ml		4056
		Ceftazidime : 0.125 mg/ml Heparin sodium : 0.5 UI/ml		4056
		Ceftazidime : 0.125 mg/ml Heparin sodium : 0.5 UI/ml		4056
		Ceftazidime : 20 mg/ml Heparin sodium : 50 UI/ml		317
		Ceftazidime : 40 mg/ml Hetastarch : 60 mg/ml		1721
		Ceftazidime : 40 & 180 mg/ml Hydromorphone hydrochloride : 2 >> 40 mg/ml		226
		Ceftazidime : 200 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Ceftazidime : 20 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Ceftazidime : 125 mg/ml Insulin : 100 UI/ml		2141
		Ceftazidime : 20 mg/ml Insulin aspart : 1 UI/ml		1508
		Ceftazidime : 20 mg/ml Insulin aspart : 1 UI/ml		1508
		Ceftazidime : 40 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Ceftazidime : 40 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829

		Ceftazidime : 125 mg/ml Isosorbide dinitrate : 0.2 mg/ml		2141
		Ceftazidime Kanamycin sulfate		3543
		Ceftazidime Kanamycin sulfate		3883
		Ceftazidime : 83.3 mg/ml Ketamine hydrochloride : 10 mg/ml		1759
		Ceftazidime : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Ceftazidime : 125 mg/ml Ketamine hydrochloride : 10 mg/ml		2141
		Ceftazidime : 20 mg/ml Ketoprofene : 3.2 mg/ml		1847
		Ceftazidime : 10 mg/ml Labetalol hydrochloride : 1 mg/ml		386
		Ceftazidime : 40 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Ceftazidime : 20 mg/ml Linezolid : 2 mg/ml		1659
		Ceftazidime : 40 mg/ml Linezolid : 2 mg/ml		1925
		Ceftazidime : 40 mg/ml Melphalan : 0.1 mg/ml		169
		Ceftazidime : 100 mg/ml Meropenem : 50 mg/ml		4389
		Ceftazidime : 100 mg/ml Meropenem : 50 mg/ml		4319
		Ceftazidime : 10 mg/ml Metronidazole : 5 mg/ml		282
		Ceftazidime : 125 mg/ml Midazolam hydrochloride : 5 mg/ml		2141
		Ceftazidime : 83.3 mg/ml Midazolam hydrochloride : 5 mg/ml		1759
		Ceftazidime : 20 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Ceftazidime : 20 & 40 mg/ml Morphine sulfate : 1 mg/ml		62
		Ceftazidime : 83.3 mg/ml N-acetylcysteine : 100 mg/ml		1759
		Ceftazidime : 125 mg/ml N-acetylcysteine : 100 mg/ml		2141
		Ceftazidime N-acetylcysteine : 200 mg/ml		3766
		Ceftazidime : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Ceftazidime Netilmicin sulfate		3883
		Ceftazidime Netilmicin sulfate		3543
		Ceftazidime : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490

		Ceftazidime : 83.3 mg/ml Nicardipine hydrochloride : 1 mg/ml		1759
		Ceftazidime : 125 mg/ml Nicardipine hydrochloride : 1 mg/ml		2141
		Ceftazidime : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Ceftazidime : 10 mg/ml Ofloxacin : 2 mg/ml		889
		Ceftazidime Ofloxacin		3883
		Ceftazidime : 200 mg/ml Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml		3574
		Ceftazidime : 40 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Ceftazidime : 40 mg/ml Paclitaxel : 1.2 mg/ml		248
		Ceftazidime Pantoprazole sodium		2090
		Ceftazidime : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Ceftazidime : 40 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Ceftazidime : 20 mg/ml Pentamidine isetionate : 3 mg/ml		275
		Ceftazidime Pentamidine isetionate		3543
		Ceftazidime : 20 & 40 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Ceftazidime : 125 mg/ml Phenytoin sodium : 50 mg/ml		2141
		Ceftazidime : 125 mg/ml Pirritamide : 2 mg/ml		2141
		Ceftazidime : 40 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Ceftazidime Potassium chloride		3883
		Ceftazidime : 40 mg/ml Propofol : 10 mg/ml		300
		Ceftazidime : 83.3 mg/ml Propofol : 1 mg/ml		1759
		Ceftazidime : 125 mg/ml Propofol : 1 mg/ml		2141
		Ceftazidime : 40 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Ceftazidime : 125 mg/ml Remifentanyl hydrochloride : 200 µg/ml		2141
		Ceftazidime : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Ceftazidime : 40 mg/ml Sargramostim : 6 §15 µg/ml		891
		Ceftazidime : 40 mg/ml Sargramostim : 10 µg/ml		335

		Ceftazidime Sodium bicarbonate		3883
		Ceftazidime Sodium bicarbonate		3543
		Ceftazidime : 125 mg/ml Sufentanil citrate : 0.005 mg/ml		2141
		Ceftazidime : 83.3 mg/ml Sufentanil citrate : 0.005 mg/ml		1759
		Ceftazidime : 40 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Ceftazidime : 20 & 100 mg/ml Tacrolimus : 5 & 20 µg/ml		814
		Ceftazidime : 20 mg/ml Tacrolimus : 1000 µg/ml		479
		Ceftazidime : 40 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Ceftazidime : 0,1 mg/ml Teicoplanine : 0,025 mg/ml		2450
		Ceftazidime : 40 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Ceftazidime : 40 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Ceftazidime : 40 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Ceftazidime : 20 mg/ml Temocilline : 83.33 mg/ml		2231
		Ceftazidime : 40 mg/ml Teniposide : 0.1 mg/ml		905
		Ceftazidime : 5 mg/ml Tenoxicam : 0,2 mg/ml		1943
		Ceftazidime : 20 mg/ml Theophylline : 4 mg/ml		317
		Ceftazidime : 125 mg/ml Theophylline : 20 mg/ml		2141
		Ceftazidime : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
		Ceftazidime : 40 mg/ml Thiotepa : 1 mg/ml		249
		Ceftazidime : 125 mg/ml Tobramycin sulfate : 6 mg/ml		2141
		Ceftazidime Tobramycin sulfate		3543
		Ceftazidime : 0.125 mg/ml Tobramycin sulfate : 0.008 mg/ml		2369
		Ceftazidime Tobramycin sulfate		3883
		Ceftazidime : 83.3 mg/ml Tobramycin sulfate : 6 mg/ml		1759
		Ceftazidime : 83.3 mg/ml Urapidil : 5 mg/ml		1759
		Ceftazidime : 125 mg/ml Urapidil : 5 mg/ml		2141

	Ceftazidime : 83.3 mg/ml Valproic acid : 100 mg/ml		1759	
	Ceftazidime : 125 mg/ml Valproic acid : 100 mg/ml		2141	
	Ceftazidime : 5 mg/ml Vancomycin hydrochloride : 5 mg/ml		3101	
		Ceftazidime : 125 mg/ml Vancomycin hydrochloride : 30 mg/ml		2141
		Ceftazidime Vancomycin hydrochloride		3543
	Ceftazidime : 5 mg/ml Vancomycin hydrochloride : 5 mg/ml		3101	
	Ceftazidime : 5 mg/ml Vancomycin hydrochloride : 5 mg/ml		3101	
	Ceftazidime : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674	
	Ceftazidime : 0.5 mg/ml Vancomycin hydrochloride : 1 mg/ml		1416	
		Ceftazidime : 22 & 200 mg/ml Vancomycin hydrochloride : 10 & 100 mg/ml		1877
	Ceftazidime : 1 >> 200 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674	
		Ceftazidime : 83.3 mg/ml Vancomycin hydrochloride : 30 mg/ml		1759
		Ceftazidime Vancomycin hydrochloride		3883
		Ceftazidime : 125 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
		Ceftazidime : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		1399
		Ceftazidime : 10 >> 200 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
		Ceftazidime : 20 mg/ml Vancomycin hydrochloride : 10 mg/ml		1959
	Ceftazidime : 40 mg/ml Vinorelbine tartrate : 1 mg/ml		84	
		Ceftazidime : 20 mg/ml Warfarin sodium : 2 mg/ml		315
	Ceftazidime : 20 mg/ml Zidovudine : 4 mg/ml		337	



método de inyección





Bibliografía

	Tipo	Publicación
3	periódico	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
57	periódico	Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304.
59	periódico	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	periódico	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	periódico	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	periódico	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	periódico	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104	periódico	Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189.
169	periódico	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	periódico	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
198	periódico	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	periódico	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
226	periódico	Walker SE, DeAngelis C, Iazzetta J. Stability and compatibility of combinations of hydromorphone and a second drug. Can J Hosp Pharm 1991 ; 44: 289-295.

244	periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	periódico	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	periódico	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	periódico	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
256	periódico	Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208.
273	periódico	Van Doorne V, Bernaards J, DeJonge P. Ceftazidime degradation rates for predicting stability in a portable infusion-pump reservoir. Am J Health-Syst Pharm 1996 ; 53: 1302-1305.
275	periódico	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
282	periódico	Rivers TE, Webster AA. Stability of ceftizoxime sodium, ceftriaxone sodium, and ceftazidime with metronidazole in ready-to-use metronidazole bags. Am J Health-Syst Pharm 1995 ; 52: 2568-2570.
285	periódico	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
287	periódico	Bednar DA, Klutman NE, Henry DW, Fox JL, Strayer AH. Stability of ceftazidime (with arginine) in an elastomeric infusion device. Am J Health-Syst Pharm 1995 ; 52: 1912-1914.
299	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	periódico	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	periódico	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
315	periódico	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
316	periódico	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.

317	periódico	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	periódico	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	periódico	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	periódico	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
337	periódico	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
360	periódico	Inagaki K, Gill MA, Okamoto MP, Takagi J. Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 2769-2772.
384	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
386	periódico	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358.
397	periódico	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
432	periódico	Marble DA, Bosso JA, Townsend RJ. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 1986 ; 43: 1732-1736.
440	periódico	Stiles ML, Tu YH, Allen LV. Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin G sodium in portable pump reservoirs. Am J Hosp Pharm 1989 ; 46: 1408-1412.
443	periódico	Stiles ML, Allen LV, Fox JL. Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 2761-2764.
445	periódico	Stewart JT, Warren FW, Johnson SM, Fox JL, Mullaney J. Stability of ceftazidime in plastic syringes and glass vials under various storage conditions. Am J Hosp Pharm 1992 ; 49: 2765-2768.
477	periódico	Nahata MC, Morosco RS, Fox JL. Stability of ceftazidime (with arginine) stored in plastic syringes at three temperatures. Am J Hosp Pharm 1992 ; 49: 2954-2956.
479	periódico	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	periódico	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.

492	periódico	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	periódico	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
500	periódico	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.
585	periódico	Das Gupta V, Bethea C, Dela Torre M. Chemical stabilities of cefaperazone sodium and ceftazidime in 5% dextrose and 0.9% sodium chloride injections. J Clin Pharm Ther 1988 ; 13: 199-205.
604	Laboratorio	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
697	periódico	Walker SE, Dratnitsaris G. Ceftazidime stability in normal saline and dextrose in water. Can J Hosp Pharm 1988 ; 41: 65-71.
814	periódico	Johnson CE, VandenBussche HL, Chio CC, Jacobson PA. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. Am J Health-Syst Pharm 1999 ; 56: 164-169.
817	periódico	Stendal TL, Klem W, Tonnesen HH, Kjonniksen I. Drug stability and pyridine generation in ceftazidime injection stored in an elastomeric infusion device. Am J Health-Syst Pharm 1998 ; 55: 683-685.
889	periódico	Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209.
891	periódico	Matsuura G. Visual compatibility of sargramostim (GM-CSF) during simulated Y-site administration with selected agents. Hosp Pharm 1992 ; 27: 200, 202, 209.
900	periódico	Pleasant RA, Vaughan LM, Williams DM, Fox JL. Compatibility of ceftazidime and aminophylline admixtures for different methods of intravenous infusion. Ann Pharmacotherapy 1992 ; 26: 1221-1226.
905	periódico	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	periódico	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	periódico	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1067	periódico	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1135	periódico	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.

1315	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1399	periódico	Cairns CJ, Robertson J. Incompatibility of ceftazidime and vancomycin. Pharm J 1987 ; 238: 577.
1410	periódico	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	periódico	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1416	periódico	Stamatakis MK, Leader G, Tracy TS. Stability of high-dose vancomycin and ceftazidime in peritoneal dialysis solutions. Am J Health-Syst Pharm 1999 ; 56: 246-248.
1423	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	periódico	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1490	periódico	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1508	periódico	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.
1611	periódico	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	periódico	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1651	periódico	Ars?ne M, Favetta P, Favier B, Bureau J. Comparison of ceftazidime degradation in glass bottles and plastic bags under various conditions. J Clin Pharm Ther 2002 ; 27: 205-209.
1656	periódico	Faouzi A, Dine T, Luyckx M, Gressier B, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Cazin JC. Stability and compatibility studies of cefaloridine, cefuroxime and ceftazidime with PVC infusion bags. Pharmazie 1994 ; 49: 425-427.
1659	periódico	Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three cephalosporin antibiotics. J Am Pharm Assoc 2000 ; 40: 509-514.
1674	periódico	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	periódico	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.

1713	periódico	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	periódico	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	periódico	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1759	periódico	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1800	periódico	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1802	periódico	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
1803	periódico	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1840	periódico	Xu QA, Trissel LA, Saenz CA et al. Stability of three cephalosporin antibiotics in autodose infusion system bags. J Am Pharm Assoc 2002 ; 42: 428-431.
1847	periódico	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1857	periódico	Farina A, Porra R, Cotichini V, Doldo A. Stability of reconstituted solutions of ceftazidime for injections: an HPLC and CE approach. J Pharm Biomed Anal 1999 ; 20-521-530.
1877	periódico	Lifshitz T, Lapid-Gortzak R, Finkelman Y, Klemperer I. Vancomycin and ceftazidime incompatibility upon vitreal injection. Br Ophtalmol 2000 ; 84: 117.
1925	periódico	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	periódico	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1943	periódico	Wang DP, Chiou AHJ, Lee DKT. Compatibility and stability of ceftazidime sodium and tenoxicam in 5% dextrose injection. Am J Health-Syst Pharm 2004 ; 61: 1924-1927.
1953	periódico	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1959	periódico	Mac Lellan C, Papadopoulos A. Precipitate formation after subconjunctival administration of ceftazidime and vancomycin. Hosp Pharm 2005 ; 40, 2: 154-155.


1982	periódico	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2042	periódico	Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal β -lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2087	periódico	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	periódico	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	periódico	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2141	periódico	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2231	periódico	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2247	periódico	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2271	Laboratorio	Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006
2369	periódico	Mason NA, Johnson CE, O'Brien MA. Stability of ceftazidime and tobramycin sulfate in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 1139 - 1142.
2450	periódico	Manduru M, Fariello A, White RL, Fox JL, Bosso JA. Stability of ceftazidime sodium and teicoplanin sodium in a peritoneal dialysis solution Am J Health-Syst Pharm 1996 ; 53: 2731 - 2734.
3012	periódico	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3091	periódico	Thalhammer F, Maier-Salamon A, Jäger W. Prüfung von Stabilität und Kompatibilität von Flucloxacillin (Floxapen®) und Ceftazidim (Fortum®) in zwei Infusionslösungen:Relevanz für die klinische Praxis. Wien Med Wochenschr 2005 ; 155, 13-14: 337-343.
3101	periódico	Wazny LD, Blake PG. Incompatibility of Vancomycin and Ceftazidime for Intraperitoneal Use. Perit Dial Int 2002 ; 22: 93-94.
3216	periódico	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3254	periódico	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.

3385	periódico	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	periódico	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Laboratorio	Cidomycin - Summary of product Characteristics. Sanofi 2011
3526	Laboratorio	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3543	Laboratorio	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3549	Laboratorio	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3574	Laboratorio	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3643	Laboratorio	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3651	periódico	Patel R.P, Shastri M.D, Bakkari M, Wanandy T, Jose M.D. Stability of the Combination of Ceftazidime and Cephazolin in Icodextrin or pH Neutral Peritoneal Dialysis Solution. Perit Dial Int 2014 ; 34:212-218
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3696	periódico	Santos C.A.D, Oliveira-Nascimento L, Knirsch M.C, Stephano M.A, Pessoa J?nior A, Penna T.C.V. Biological and physicochemical stability of ceftazidime and aminophylline on glucose parenteral solution. Braz J Pharm Sci 2012 ; 48, 4: 691-698.
3728	periódico	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3757	periódico	Bourget P, Amin A, Dupont C, Abely M, Desmazes-Dufeu N, Dubus J.C, Jouani B.-L., Merlette C, Nov?-Josserand R, Pages J, Panzo R How To Minimize Toxic Exposure to Pyridine during Continuous Infusion of Ceftazidime in Patients with Cystic Fibrosis? Antimicrob Agents Chemother 2014 ; 58 : 2849-2855.
3766	periódico	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	periódico	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3824	periódico	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	póster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	póster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015


3829	póster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3883	Laboratorio	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3888	periódico	Ranganathan D, Naicker S., Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). Perit Dial Int 2016 ; 36:421-426.
3964	periódico	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	periódico	Staven V, Herra I, Wang S, Grönlie I, Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	periódico	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3997	periódico	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4032	póster	Daul A, Vigneron J, Zenier H, May I, Demor? B. Stability of frozen ceftazidime in polypropylene syringes for intravitreal injection. EAHP Congress - Paris 2013
4055	periódico	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4056	periódico	Kandel S, Zaidi S, Wanandy T, Ming L, Castelino R, Sud K, Patel R. Stability of ceftazidime and heparine in four different types of peritoneal dialysis solutions. Perit Dial Int 2017
4145	periódico	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	periódico	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4370	periódico	Staven V, Wang S, Gronlie I, Tho I. Physical stability of an all-in one parenteral nutrition admixture for preterm infants upon mixing with micronutrients and drugs EJHP 2018 2018;0:1-7
4389	periódico	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	periódico	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4434	periódico	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.

4440	periódico	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.
4603	periódico	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4634	periódico	Loeuille G, D'Huart E, Vigneron J, Nisse YE, Beiler B, Polo C, Ayari G, Sacrez M, Demoré B, Charmillon A. Stability studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy. Antibiotics 2022 ;11,4: 458
4693	periódico	Shen H, Fu Y, Chen Y, Xia W, Jia Z, Yu Q, Zhang L, Han L. Compatibility and Stability of Ten Commonly Used Clinical Drugs in Pediatric Electrolyte Supplements Injection. Drug Design Dev Ther 2022 ;16:1433-1440.
4742	periódico	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	periódico	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4922	periódico	Wanandy T, Handley SA, Le TTA, Lau WY, Turner ME, Wiese MD. Stability of Antibiotics for Use in the Testing of Immediate Drug Allergy Reactions. J Allergy Clin Immunol Pract 2024 13, 2: 343-352.
4943	periódico	D'Huart E, Boutouha I, Berardi C, Vigneron J, Demore B, Charmillon A. Stability of Nine Time-Dependent Antibiotics for Outpatient Parenteral Antimicrobial Therapy (OPAT) Use Antibiotics 2025 Antibiotics 2025, 14(5),

Stabilis



Ceftazidime



La estabilidad de las preparaciones farmacéuticas

		500 mg Fortum®	Cloruro de benzalconio 6,4 mg BSS solution® 10 ml	-20°C		75		4197
		100 mg Ceftazidime Biotum®	Borato fenilmercúrico 0,04% 250 mg β-feniletilalcohol 40 mg Tampón citrato pH 6,24>>9,21g	4°C		24		3289
		500 mg Ceftazidime Biotum®	Tampón citrato pH 6,64>>10g	4°C		21		3289
		100 mg Ceftazidime Biotum®	Tampón citrato pH 6,24>>10g	4°C		27		3289
		500 mg Ceftazidime Biotum®	Borato fenilmercúrico 0,04% 250 mg β-feniletilalcohol 40 mg Tampón citrato pH 6,64>>9,21g	4°C		15		3289
		100 mg Ceftazidime Biotum®	Alcohol polivinílico η = 43,2 mPas pH 5,51 Tampón citrato pH 6,10 >>4,950 g	4°C		18		3289
		100 mg Ceftazidime Biotum®	Alcohol polivinílico η = 43,2 mPas pH 5,51 Borato fenilmercúrico 0,04% 250mg β-feniletilalcohol 40mg Tampón citrato pH 6,10 >>4,805g	4°C		18		3289
		500 mg Ceftazidime Biotum®	Alcohol polivinílico η = 43,2 mPas pH 5,51 Tampón citrato pH 6,10 >>4,750g	4°C		15		3289
		500 mg Ceftazidime Biotum®	Alcohol polivinílico η = 43,2 mPas pH 5,51 Borato fenilmercúrico 0,04% 250mg β-feniletilalcohol 40mg Tampón citrato pH 6,10 >>4,605g	4°C		12		3289
		500 mg Fortum®	Cloruro de benzalconio 6,4 mg BSS solution® 10 ml	4°C		7		4197
		1000 mg Fortum®	SnoTears® >> 20 mL	7°C		7		2717
		500 mg Fortum®	SnoTears® 10 ml	7°C		5		2708
		400 mg ? = Arrow®	NaCl 0.9% >> 8 mL	2-8°C		10		4041



Factores que influyen sobre la estabilidad

					3289
	25°C				2708 4264
					3289
	Alcohol polivinílico				3289
	Borato fenilmercúrico				3289
	β-feniletilalcohol				3289



Bibliografía

	Tipo	Publicación
2708	periódico	Barnes AR, Nash R. Stability of ceftazidime in a viscous eye drop formulation J Clin Pharm Ther 1999 ; 24: 299-302
2717	periódico	Barnes AR. Determination of ceftazidime and pyridine by HPLC: application to a viscous eye drop formulation. J Liquid Chrom 1995 ; 18: 3117-3128.
3289	periódico	Kodym A, Hapka-Zmich D, Golab M, Gwizdala M. Stability of ceftazidime in 1% and 5% buffered eye drops determined by HPLC method. Acta Pol Pharm 2011 ; 68, 1: 99-107.
4041	póster	Jobard M, Brandely-Piat M-L, El Deeb G, Labat L, Cros C, Chast F, Batista R. Etude de stabilité d'un collyre de ceftazidime à 50mg/ml conditionné en flacon de polyéthylène basse densité. SNPHPU Congress 12th 2017
4197	periódico	Gautier E, Saillard J, Deshayes C, Vrignaud S, Lagarce F, Briot T. Stability of a 50 mg/mL Ceftazidime Eye-Drops Formulation. Pharmaceutical Technology in Hospital Pharmacy 2018 ;3,4:219-226
4264	periódico	Karampatakis V, Papanikolaou T, Giannousis M, Goulas A, Mandraveli K, Kilmpasani M, Alexiou-Daniel S, Mirtsou-Fidani V. Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus. Acta Ophtalmol 2008



Diccionario

	Antibiótico		Injectables
	Nombre comercial		Estabilidad en solución
	Envase		Molécula
	Concentración		Temperatura
	Conservación		Duración de la estabilidad
	biosimilar		datos contradictorios
	Bibliografía		Vidrio
	Agua para preparación inyectable		A cubierto de la luz
	Día		No precisada
	Hora		Con o sin luz
	Cloruro de sodio 0,9%		Luz
	Glucosa 5%		NaCl 0.9% + fenol 0.4%
	Cloruro de polivinilo		Dianéal® PD2 1.5% Glucosa (Baxter)
	Extraneal® (Baxter)		Polietileno
	Polipropileno		Poliolefina
	Etilén-vinil-acetato		jeringa polipropileno
	Elastómero de poliisopreno		Elastómero de silicona
	Elastómero (no especificado)		Estabilidad en mezcla
	Solvente		Molécula
	No precisado		Ninguno
	Dianéal® PD2 4.25% Glucosa (Baxter)		Dianéal® PD2 2.5% glucose (Baxter)
	Factores que influyen sobre la estabilidad		Provoque
	Aumento de la estabilidad		NaHCO3
	Degradación		Aumento
	Disminución de la estabilidad		Precipitación
	Compatibilidades		Compatible
	NaCl 0,225 % + glucosa 3.75 %		Nutrición parenteral (con lípidos)
	Incompatibilidad no especificada		Incompatible
	Ringer lactato		Turbidez en 4 horas
	Inestabilidad química		Precipitación inmediata

	Modificación de pH > 1 unidad de pH		Turbidez inmediata
	Pérdida de turbidez		Nutrición parenteral (libre de lípidos)
	NaCl 0,45% Glucosa 5%		Glucosa 30%
	Cambio de color		específico disolvente
	Turbidez en una hora		Precipitación después de 4 horas.
	Cambio de color después de 4 horas.		Inestabilidad inmediata de la emulsión
	Dianéal® 1.5% glucose (Baxter)		Dianéal® 2.5% glucose (Baxter)
	Dianéal® 4.25% glucose (Baxter)		Turbidez en 24 horas
	método de inyección		Intravenoso
	Perfusión intravenosa		Intramuscular
	Intratecal		Bibliografía
	Gotas oculares		La estabilidad de las preparaciones farmacéuticas
	Origine		Excipiente
	Frasco para medicamentos inyectables		Botella de plástico
	Diccionario		